Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Abdominal Adipose Tissue Fibrosis as an Obesity Biomarker in Clinical Practice

Zorzano-Martínez M., Pallares J., Bueno M., Salinas-Roca B., Buenaventura-Collazos D., Hernández C.

Prospective Study with a reported sample of 58 on Type 2 Diabetes, published in Obes Facts (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Obes Facts (2026)
Reported sample size
58
Source database
Europe PMC
PMID
41632723
PMCID
PMC12987678
DOI
10.1159/000550517

Abstract (original English)

Introduction The aims of the study were to describe a biopsy procedure to obtain subcutaneous adipose tissue (SAT) samples for fibrosis assessment in patients with adipose-based chronic disease (ABCD) and to explore potential associations between SAT fibrosis and comorbidities. Methods Single-center, cross-sectional study conducted at the Arnau de Vilanova University Hospital (Lleida, Spain) between January and December 2024. We included patients aged 18-65 years attending their first appointment in the Obesity Unit. Between-group comparisons were performed using Student's t-test for continuous variables and chi-square tests for categorical variables, and correlations were assessed using Spearman's rank correlation coefficient. Results 58 patients were recruited and 50 were included in the final analysis. Most were female (76.0%), with a mean age of 47.1 years (SD: 10.8), and a mean BMI of 46.3 kg/m2 (SD: 5.0). The biopsy technique evolved over time, reducing the procedure duration from 55 min to under 10 min without any adverse events. SAT fibrosis was observed in 10 patients (20.0%), who showed a higher prevalence of type 2 diabetes (50.0% vs. 15.0%, p = 0.017), significantly higher aspartate transaminase and gamma-glutamyl transferase, and elevated signs of liver fibrosis. Conclusion SAT fibrosis was associated with ABCD comorbidities and could serve as a tool for risk strat

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research